BOSTON SCIENTIFIC CORP 8-K

What Happened
Boston Scientific Corporation (filed July 27, 2026) announced that its Board approved a new global restructuring program (the "2026 Restructuring Plan") on July 21, 2026. The plan, beginning in 2026 and expected to be substantially complete by the end of 2029, targets supply chain optimization (including transferring production lines), functional transformation, and organizational changes. The company expects some headcount reductions as a result of the plan.

Key Details

• Total estimated pre-tax charges: $700 million to $800 million.
• Estimated future cash outlays: ~$600 million to $700 million.
• Expected reduction in gross annual pre-tax expenses: approximately $500 million (savings to be largely reinvested in growth initiatives).
• Estimated cost breakdown: Transfer costs $300–$350M; Termination benefits $275–$300M; Other (consulting, contract cancellations, accelerated depreciation, asset write-offs, program management) $125–$150M.
• Timeline: actions start in 2026 and are expected to be substantially completed by end of 2029; employee impact plans will be developed per region and local law.

Why It Matters
The restructuring will create near-term charges and cash outflows that will reduce reported earnings in the periods when charges are recognized, while aiming to lower ongoing operating costs by roughly $500M annually once benefits are realized. Investors should weigh the short-term earnings impact from the $700–$800M charges against the potential long-term margin and cash-flow improvements; the filing also notes forward-looking risks and uncertainties that could affect outcomes.